Valuation: Agios Pharmaceuticals, Inc.

Market Cap 2.04B 1.8B 1.69B 1.54B 2.89B 196B 2.91B 20.31B 7.87B 99.72B 7.66B 7.5B 325B P/E 2026 *
-6.02x
P/E 2027 * -9.25x
Enterprise Value 1.78B 1.57B 1.48B 1.35B 2.52B 171B 2.54B 17.75B 6.88B 87.14B 6.7B 6.55B 284B EV / Sales 2026 *
9.77x
EV / Sales 2027 * 5.42x
Free-Float
77.8%
Yield 2026 *
-
Yield 2027 * -
1 day-3.77%
1 week-0.15%
Current month-2.32%
1 month-0.57%
3 months-7.56%
6 months+17.04%
Current year+20.87%
1 week 31.37
Extreme 31.37
35.36
1 month 31.37
Extreme 31.37
35.38
Current year 24.29
Extreme 24.29
44.09
1 year 22.24
Extreme 22.24
46
3 years 19.8
Extreme 19.795
62.58
5 years 16.75
Extreme 16.75
62.58
10 years 16.75
Extreme 16.75
99.82
Manager TitleAgeSince
Chief Executive Officer 57 08/08/2022
Director of Finance/CFO 51 26/09/2022
Chief Tech/Sci/R&D Officer 47 01/09/2021
Director TitleAgeSince
Director/Board Member 66 09/12/2014
Director/Board Member 73 23/06/2015
Director/Board Member 73 27/05/2017
Date Insider Type Main position Quantity % Market Cap. Importance
04/08/26 Sell

Chief Technology Officer

-30,000 0.0504%
08/07/26 Free

Director

2,894 0.0049%
01/07/26 Exercice

Chief Technology Officer

20,757 0.0349%
Change 5-day change 1-year change 3-year change Capi.($)
-3.77%-0.15%-13.12%+34.12% 2.04B
-3.30%+2.97%+54.99%+104.15% 74.18B
-0.12%-1.63%+33.14%+74.86% 59.55B
+2.71%-0.84%-16.39%+364.46% 25.84B
+0.81%+3.58%+1.01%-5.14% 24.73B
-1.05%+2.58%+24.27%-10.32% 20.87B
-1.70%-4.15%+147.82%+325.69% 15.32B
+2.15%+2.06%+45.57%+169.79% 14.06B
-0.43%-5.32%-14.46%+775.94% 13.12B
+0.04%-3.00%+15.76%+234.69% 11.85B
Average -0.47%-0.35%+27.86%+206.82% 26.16B
Weighted average by Cap. -0.74%-0.19%+34.55%+159.31%

Financials

2026 *2027 *
Net sales 182M 161M 151M 138M 258M 17.52B 260M 1.82B 704M 8.92B 685M 670M 29.01B 351M 309M 291M 265M 496M 33.69B 500M 3.49B 1.35B 17.14B 1.32B 1.29B 55.79B
Net income -338M -297M -280M -256M -478M -32.45B -482M -3.36B -1.3B -16.51B -1.27B -1.24B -53.74B -230M -202M -191M -174M -325M -22.07B -328M -2.29B -887M -11.23B -863M -845M -36.55B
Net Debt -258M -227M -214M -195M -364M -24.73B -367M -2.56B -993M -12.59B -967M -946M -40.96B -137M -121M -114M -104M -194M -13.19B -196M -1.37B -530M -6.71B -516M -505M -21.84B
Logo Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Employees
540
Date Price Change Volume
25/09/26 $32.90 -3.77% 1,592,306
23/09/26 $34.19 -2.23% 752,478
22/09/26 $34.97 +3.00% 1,170,409
21/09/26 $33.95 +2.66% 884,550
18/09/26 $33.07 -1.61% 1,566,179
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
34.19USD
Average target price
46.25USD
Spread / Average Target
+35.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGIO Stock